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Summary
Background.— Heart failure is the leading cause of hospital admissions and an economic burden.
In accordance with European guidelines, a dedicated heart failure unit was created in René
Dubos Hospital (Pontoise, France) in 2002.
Aim.— To evaluate the impact of an in-hospital heart failure management unit on heart failure
prognosis.
Methods.— We conducted a descriptive study of all-cause in-hospital mortality and heart failurePrognosis related readmission rates in the year after the ﬁrst admission for heart failure, from January
1997 to December 2007. The Chi2 test, a trend test and linear regression were performed.
Results.— There were no signiﬁcant differences in patient characteristics (age, sex, diabetes
mellitus, left ventricular ejection fraction < 45%) other than renal insufﬁciency, in patients
admitted for heart failure from 1997 to 2007. After the creation of the heart failure unit,
we observed a signiﬁcant decrease in heart failure related readmission rate from 21.7% in 2002
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to 15.6% in 2007 (p < 0.0001), whereas there was no difference in this rate before the creation
of the unit (34.3% in 1997 and in 2001; p = 0.90). All-cause in-hospital mortality rate decreased
from 9.3% in 1997 to 5.1% in 2007 (p < 0.0001) and showed a tendency to decrease after the
creation of the heart failure unit (p = 0.06).
Conclusion.— Heart failure related readmission rates in new patients in the year after the ﬁrst
admission for heart failure reduced dramatically after the creation of the heart failure unit.
All-cause in-hospital mortality in heart failure patients decreased over the 10-year study period.
© 2010 Elsevier Masson SAS. All rights reserved.
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Résumé
Introduction.— L’insufﬁsance cardiaque (IC) est une des causes majeures d’hospitalisation et
représente un fardeau économique important. En accord avec les recommandations européen-
nes, une unité thérapeutique d’insufﬁsance cardiaque (UTIC) a été créée en 2002 à l’hôpital
René Dubos (Pontoise, France).
Objectif.— Évaluer l’impact de la création d’une UTIC sur le pronostic des patients hospitalisés
pour IC.
Méthodes.— Nous avons réalisé une étude descriptive du taux de mortalité intrahospitalière
toutes causes confondues chez les patients hospitalisés pour IC ainsi que du taux de réhospi-
talisation pour IC dans l’année suivant la première hospitalisation pour IC, de janvier 1997 à
décembre 2007. Le test du Chi2, le test de tendance et une régression linéaire ont été utilisés.
Résultats.— Entre 1997 et 2007, les caractéristiques des patients hospitalisés pour IC n’étaient
pas signiﬁcativement différentes (âge, sexe, diabète, FEVG< 45%), exception faite de
l’insufﬁsance rénale. Après la création de l’UTIC en 2002, nous avons observé une diminution
signiﬁcative du taux de réhospitalisations pour IC de 21,7 % en 2002 à 15,6 % en 2007 (p < 0,0001)
alors que ce taux ne différait pas avant la création de l’UTIC (34,3 % en 1997 et 2001; p = 0,90).
Le taux de mortalité intrahospitalière toutes causes confondues a diminué en passant de 9,3 %
en 1997 à 5,1 % en 2007 (p < 0,0001) avec une tendance à la diminution suite à la création de
l’UTIC (p = 0,06).
Conclusion.— Le taux de réhospitalisations pour IC dans l’année suivant la première hos-
pitalisation pour IC a diminué signiﬁcativement après la création de l’UTIC. La mortalité
intrahospitalière toutes causes confondues chez les patients insufﬁsants cardiaques a diminué
signiﬁcativement durant ces dix dernières années.
© 2010 Elsevier Masson SAS. Tous droits réservés.
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BNP B-type natriuretic peptide
CI conﬁdence interval
ESC European Society of Cardiology
HF heart failure
LVEF left ventricular ejection fraction
RCT randomized controlled trials
Background
In many industrialized countries, HF is the leading cause
of hospitalization for patients over 65 years of age [1] and
about 40% of patients are readmitted in the year after their
ﬁrst admission for HF [2]. The overall prognosis for systolic
HF is poor and the 1-year survival rate for severe HF is
lower than that for most cancers [3]. HF also presents a
huge economic burden [4]. In developed countries, mainly
because of readmissions, HF accounts for up to 1—2% of
total health costs [5] and this is expected to continue to
increase in the future [4,6]. Studies from different settings
c
l
f
mave shown that non-compliance with medication, diet or
ymptom monitoring causes the majority of readmissions
ue to HF [7].
Over the past decade, we have seen an explosion of new
reatment options for patients with HF, with a documented
eneﬁt for clinical outcome. As described recently in the
pdated guidelines from the ESC [8], management of chronic
F is a complex issue and an organized system of specialist
F care should be established to improve the outcome of
atients with HF.
Since the introduction of the ﬁrst HF programme in
urope [9,10], different models have been developed in sev-
ral European countries, organized and delivered according
o local and national healthcare needs. Several RCTs have
ompared these kinds of programmes for HF with usual care
11—13], and meta-analyses [14—17] have conﬁrmed that
hey reduce mortality and hospital readmissions and indi-
ate strong potential improvements in quality of life and
ost savings [18,19].Unfortunately, only a few European countries have a
arge number of organized structures for HF care and
ollow-up [20]: of the 33 RCTs included in the last
eta-analysis [17], only ﬁve involved multidisciplinary and
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n-hospital approaches. All other RCTs involved nurse-led or
harmacist-led education or after-discharge management.
his emphasizes the importance of creating an in-hospital HF
anagement programme, in terms of efﬁcacy for patients.
In order to guide and stimulate the further develop-
ent of HF management programmes in France, the aim
f this study was to evaluate the impact of an in-hospital
F unit (that included an in-patient hospitalization unit, an
utpatient unit and an education structure) on all-cause in-
ospital mortality rates and HF-related readmission rates in
he year after the ﬁrst admission for HF.
ethods
ata sources
ach patient admitted to René Dubos Hospital (Pontoise,
rance) from January 1997 to December 2007 was recorded.
urthermore, as part of standard procedure, information
rom patient case records was used, at the time of hospital
ischarge, to code diagnoses according to the 10th Revision
f the World Health Organization International Classiﬁcation
f Diseases [21]. A single cardiologist coded the diagnoses to
nable each individual’s hospitalization record since 1997 to
e analysed with a high degree of accuracy. This cardiologist
eviewed all charts and certiﬁed the diagnosis. The present
nalysis was planned retrospectively to ﬁnd differences
n HF-related readmission rates and all-cause in-hospital
ortality rates after the initiation of the HF management
nit.
atients
ll patients were scheduled for a full clinical examina-
ion and control of medication and comorbidity. In all
atients, the New York Heart Association class was esti-
ated. Blood chemistry was analysed by standard methods
nd BNP was measured during outpatient hospitalization
scheduled within 1 month of the index hospitalization) by
n in vitro immunoassay using a triage R meter (Biosite®
nc., San Diego, CA, USA). Transthoracic echocardiogra-
hy was performed during the index hospitalization using
Philips/Hewlett-Packard Sonos 5500® echocardiography
ystem (Philips®, Amsterdam, Netherlands). LVEF was cal-
ulated according to the recommendations of the ESC
8].
According to the recommendations [8,22], all patients
ith HF class II—IV (New York Heart Association) and left
entricular dysfunction assessed by transthoracic echocar-
iography after medical stabilization were eligible for
nclusion.
HF main diagnosis was assessed from information in the
ospital records at discharge. Recorded admissions from
anuary 1997 to December 2007 were screened to identify
nd select only those patients with a ﬁrst admission caused
rimarily by the following (International Classiﬁcation of
iseases): HF (I50), congestive HF (I50.0), left ventricu-
ar dysfunction (I50.1), cardiogenic shock (R57.0). We then
xcluded all patients who had a previous hospital admission
or HF according to their medical records and after a reliable
namnesis.
S
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F management unit
n HF management unit was created in January 2002 in René
ubos Hospital (Pontoise, France). Each patient with a new
iagnosis of HF was included directly in the HF management
rogramme at discharge.
An outpatient hospitalization was scheduled within 1
onth of the ﬁrst hospital discharge. The multidisciplinary
rogramme involved cardiologists, nurses, dieticians and
hysiotherapists, and included patient education, drug
itration, diagnostic testing, telephone consultation, phys-
cal examination and diagnostic tests. Patient education
ncluded a combination of verbal and written informa-
ion. Intensive pharmacological treatment was based on
vidence-based guidelines current at the time of study
22]. Drug titration was mainly protocol-led and included
iuretics, beta-blockers, angiotensin-converting enzyme-
nhibitors, angiotensin II receptor blockers and aldosterone
eceptor antagonists. Diagnostic tests were routine lab-
ratory tests (creatinine, potassium), BNP concentration,
lectrocardiogram and 6-minute walk test. All patients
nderwent a complete transthoracic echocardiography
ssessment in the left lateral position. Parasternal long
nd short axis, and apical two- and four-chamber views
ere recorded. Colour ﬂow and Doppler measurements were
ndertaken for assessment of valves.
Left ventricular systolic dysfunction was measured by the
impson method. Left ventricular diastolic dysfunction was
ssessed according to evidence-based guidelines current at
he time of study (presence of normal or only mildly abnor-
al left ventricular systolic function; evidence of abnormal
eft ventricular relaxation, ﬁlling, diastolic distensibility or
iastolic stiffness) [23].
HF was diagnosed using the ESC [8,22] criteria, i.e.
ymptoms of HF, objective evidence of left ventricular dys-
unction and/or response to treatment directed towards HF.
A follow-up plan was devised for each patient, aiming for
onthly visits alternating between the general practitioner
nd HF unit, although the patients were free to see their
eneral practitioner whenever they wished. Subsequently,
roup education sessions were planned for within 6 weeks
f hospital discharge. These sessions were run by a cardiolo-
ist and the study nurse. The study team at the HF unit was
vailable for consultation during normal working hours and
eceived calls from both patients and their general prac-
itioners. At times of worsening symptoms, patients were
dvised to see their general practitioner in the ﬁrst instance.
ndpoints
he primary endpoint was the HF-related readmission rate.
lthough there is no unanimous agreement on the endpoints
o be used for HF trials, we consider readmission rate to
e clinically relevant, related directly to the primary goal
f the trial. The secondary endpoint was the all-cause in-
ospital mortality rate of patients admitted for HF. Finally,
verage length of hospital stay was recorded from 1997 to
007.tatistical analysis
ontinuous variables are expressed as mean± standard devi-
tion, and categorical data as numbers and percentages.
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ur main outcome was HF-related readmission rate. The
F-related readmission rate was measured as number of
ew patients readmitted for HF within the year after the
rst admission for HF, over the total of new patients admit-
ed for HF in the same year. Our secondary outcome was
ll-cause in-hospital mortality rate, which was measured as
he number of patients who died during hospitalization for
F, over the total number of patients admitted for HF. We
lso measured the length of hospital stay during the 10-year
ollow-up.
Comorbidity rates were compared using the Chi2 test. HF-
elated readmission rate and all-cause in-hospital mortality
ate were compared using the two-sided Cochran-Armitage
est for trend. The mean age and length of hospital stay were
ompared using linear regression. A p < 0.05 was considered
tatistically signiﬁcant. Statistical analyses were performed
sing SAS 9.1 software (SAS Institute Inc., Cary, NC, USA).
esults
ample characteristics
rom January 1997 to December 2007, the total number of
ew patients admitted for HF was 3200 (range per year:
79—377 patients). The population consisted of 1556 men
48.6%), with a mean age per year ranging from 68.5± 15.7
ears to 74± 12.7 years; 53.7% of patients presented with
ystolic HF (LVEF < 45%), 15.4% had renal insufﬁciency and
0.2% had diabetes mellitus. Concerning these character-
stics, no signiﬁcant differences were found from 1997 to
007, except for renal insufﬁciency: there was a signiﬁcant
ncrease after the creation of HF unit, from 10% (n = 31) in
002 to 22% (n = 70) in 2007 (p = 0.001) (Table 1). Overall, 58%
f patients had arterial hypertension and 62% had coronary
rtery disease.
Regarding treatments, after index hospitalization, 82% of
atients received renin-angiotensin system blockers and 52%
f patients received beta-blockers. After outpatient hospi-
alization, 92% of patients received beta-blockers.
BNP concentration measured during outpatient hospital-
zation scheduled within 1 month after index hospitalization
as 258± 290 pg/mL.
F-related readmission rate
efore the creation of HF unit (1997 to 2001), the HF-related
eadmission rate ranged from 32.1% to 36.2%, with no sig-
iﬁcant difference (p = 0.90). After the creation of the HF
anagement unit, starting from 2002, we observed an over-
ll decrease in the HF-related readmission rate, ranging
rom 21.7% in 2002 to 15.6% in 2007 (p < 0.0001). Overall, we
bserved a dramatic decrease in the HF-related readmission
ate from 1997 to 2007, with a highly signiﬁcant difference
p < 0.0001) (Table 2, Fig. 1).
ll-cause in-hospital mortality ratehe all-cause in-hospital mortality rate for patients hospi-
alized for HF appeared to decrease signiﬁcantly during the
0-year follow-up (p < 0.0001). Mortality rate did not differ
efore the creation of HF unit (from 1997 to 2001; p = 0.638),
94 S. Zuily et al.
Table 2 Heart failure-related readmission rate in the year after initial discharge from the hospital.
Year 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Number of new patients admitted/year 198 179 221 265 286 314 338 352 377 350 320
Number of new patients readmitted for
HF in the year after the ﬁrst admission
for HF
68 59 80 85 98 68 108 94 94 59 50
HF-related rate of readmission of new
patients in the year after the ﬁrst
admission for HF
34.3 33.0 36.2 32.1 34.3 21.7 32.0 26.7 24.9 16.9 15.6
HF: heart failure.
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iigure 1. After the creation of the heart failure unit, a dramatic
ecrease in the heart failure-related readmission rate in the year
fter initial discharge from hospital was observed.
002—2007 linear trend.
ut decreased after the creation of the HF unit, without
eaching statistical signiﬁcance (from 2002 to 2007; p = 0.06)
Fig. 2)verage length of hospital stay
he average length of hospital stay decreased during the
0-year follow-up (p = 0.027—0.3 days per year).
igure 2. All-cause in-hospital mortality rate for patients hospi-
alized for heart failure decreased signiﬁcantly during the 10-year
ollow-up.
997—2007 linear trend.
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n this study, after the creation of HF management unit,
e observed a signiﬁcant decrease in the HF-related read-
ission rate from 2002 to 2007, whereas there was no
ifference in rates before the creation of the HF manage-
ent unit, i.e. from 1997 to 2002. The all-cause in-hospital
ortality rate for patients hospitalized for HF decreased
igniﬁcantly during the 10-year follow-up and we observed
trend towards a decrease after the creation of the HF
nit, from 2002 to 2007, but without statistical signiﬁcance.
inally, we noticed that the average length of hospital stay
ecreased during the 10-year follow-up.
The increase in the HF-related readmission rate, in par-
icular in 2003, can be explained on the one hand by the heat
ave that occurred in August 2003 in our country, which led
o many hospital admissions and deaths related not only to
F [24], and on the other hand, by the absence of the car-
iologist involved in the HF unit due to health problems. A
arge drop in readmission rate immediately after the cre-
tion of the programme can be explained by the motivation
f the staff.
Concerning renal insufﬁciency, we suppose that the
ncrease since the creation of the HF unit can be explained
y treatment: when used in optimal doses to treat patients
ith HF, renin-angiotensin system blockers improve clinical
utcomes but can cause renal impairment [25]. Concerning
ll other comorbidities, because no signiﬁcant differences
ere found from 1997 to 2007, we suppose that HF-related
eadmission rate evolution was not related to these comor-
idities.
Several models of follow-up care for HF patients exist in
urope but a few European countries have a large number of
rganized programmes for HF [20]. For example, in Sweden,
he concept of HF nurses working in an outpatient clinic
rst occurred in the literature in 1983. Since then, many HF
linics have been created and evaluated by RCTs. In France,
he lack of HF clinics and such RCTs led us to conduct only
bservational studies.
In Medicare-managed care plans, there is widespread use
f HF disease management. However, the programmes focus
rimarily on patient self-management rather than on engag-
ng physicians in medication management and compliance
ith guidelines. Mehrotra et al. [26] raised the concern that
hese programmes will not be able to achieve the quality
mprovement and cost savings demonstrated previously in
linical trials of HF disease management.
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Despite these differences, our results are quite similar to
the results of international studies. In a recent trial, Doughty
et al. [27] concluded that the main effect of integrated HF
management was attributable to the prevention of multi-
ple admissions and associated reduction in bed days. They
showed a decrease in hospital admission rate in the inter-
vention group involved in HF management compared with
usual care for patients with HF. The main effect of HF man-
agement intervention was attributable to the prevention of
multiple all-cause readmissions. In a recent meta-analysis,
Roccaforte et al. [17] aimed to re-evaluate the evidence
supporting the effectiveness of an HF management pro-
gramme in improving relevant clinical outcomes —mortality
ﬁrst— in a much larger sample of studies and patient popula-
tions. Eight trials showed a statistically signiﬁcant reduction
in the HF-related hospitalization rate in the interventional
group compared with usual care; none demonstrated an
increase. The combined odds ratio (Yusuf-Peto method) was
0.58 (CI 0.50—0.67), but with a statistically signiﬁcant test
for heterogeneity, without identifying any study as the likely
source of heterogeneity. The combined relative risk was 0.69
(CI 0.63—0.77, no heterogeneity) and the random effect
odds ratio was 0.56 (CI 0.42—0.71, with some degree of
heterogeneity). This meta-analysis conﬁrmed, extended and
updated ﬁndings published previously by McAlister et al.
[16].
Our results can also be compared with those observed in
France. Firstly, based on the French database, HF-related
admission rates increased from 1997 (242.6/100,000 resi-
dents) to 2005 (290.3/100,000 residents) [28]. Our results
are in agreement and showed that the HF-related admission
rate per year increased from 1997 (n = 198) to 2007 (n = 320).
In parallel, the HF-related readmission rate decreased after
2002, in part due to HF unit hospitalization and disease
management. Secondly, HF-related mortality decreased sig-
niﬁcantly from 1990 to 2005 (−34%) and from 2000 to
2005 (−13%) [28]. Our results are similar because the
all-cause in-hospital mortality rates for patients hospital-
ized for HF decreased signiﬁcantly during the 1997—2007
period.
Multidisciplinary care of HF remains cost-effective and
cost-beneﬁcial when combined with optimal medical care.
The signiﬁcant clinical and cost beneﬁts suggest that this
intensive approach to multidisciplinary care and medical
management should become the standard of care for HF
[29]. Our results suggest that the average length of hospi-
tal stay decreased during the 10-year follow-up. Although
our study is not designed for economic evaluation, we can
suppose that, because of the reduction in hospital readmis-
sions, the overall cost of care will have decreased after the
creation of the HF unit.
Every clinic needs to undergo regular evaluation. The
present study supposed that the readmission rate could be
used to evaluate the efﬁciency of the work of the HF unit.
This instrument could be validated in order to improve the
HF unit’s evaluation. It is of great importance to continue to
evaluate the clinics from a health-economic perspective and
for patient satisfaction, quality of life and compliance with
valid and reliable instruments. Actually, ESC guidelines [8]
recommend that an organized system of specialist HF care
should be established to improve outcomes of HF patients.
Unfortunately, only a few European countries have a large
o
p
t
e
h95
umber of organized programmes for HF care and follow-up
20].
trength and limitations
s in any observational study, there are a number of limi-
ations that require comment. We ﬁnally chose readmission
ate as our primary endpoint. In spite of some limitations,
e estimate that readmission rate was clinically relevant,
elated directly to the primary goal of the trial. Zanolla et al.
30] demonstrated that the event of hospitalization appar-
ntly represents an objective, ‘‘hard’’ endpoint; patients
ith HF also have an impaired quality of life and increased
orbidity requiring frequent hospitalizations. Among the
uropean programmes that evaluated care, frequency of
eadmission was the outcome monitored most frequently,
ollowed by patient satisfaction and quality of life [20].
Moreover, we have to be aware of the limitations inher-
nt in data collected by ICD codes, which we have to rely on
o identify the study sample. It is, however, very difﬁcult to
nsure that all the factors were taken into account, partic-
larly the grade of HF, the type and severity of ventricular
ysfunction, the comorbidities and the number and type of
rugs with their possible interactions and side-effects that
an inﬂuence the rate of adverse events.
Furthermore, even if only in-hospital data were collected
nd the number of deaths that occurred outside hospital
as unknown, this might not have consequences for the HF-
elated readmission rate and cannot be a competing risk for
eadmission.
Finally, we conducted an observational study and not
randomized prospective study in order to assess the
ecrease in HF-related readmission rates and all-cause in-
ospital mortality rates. This was an observational study and
ata were collected retrospectively; as such, it has signiﬁ-
ant limitations (no randomized and controlled groups, lack
f comparability between patients through the years). How-
ver, our results are similar to data available in and outside
rance.
Despite these limitations, we have highlighted the poten-
ial beneﬁt of specialist care in optimizing the management
f newly diagnosed HF patients.
onclusion
ince the HF intensive integrated management was devel-
ped at René Dubos Hospital (Pontoise, France), HF-related
eadmission rates in new patients within the year after the
rst admission for HF decreased dramatically. Furthermore,
ortality in HF patients was conﬁrmed to have decreased
uring the 10-year study period, thereby conﬁrming the
mpact of HF care management on HF prognosis. Because of
he limitations, further prospective studies will be necessary
o conﬁrm these ﬁndings and to study the cost implications
f this strategy.
In the future, evaluation methods such as certiﬁcation
f special competency may be required to ensure that
roviders have appropriate training and clinical experience
o treat this very important disease process. This kind of
valuation, based on an endpoint like readmission rate, may
elp the HF management unit to justify their programme.
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